Nerve stimulation for treating disorders

• US 7,885,709 B2
• Filed: 09/22/2005
• Issued: 02/08/2011
• Est. Priority Date: 08/31/2001
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: BioControl Medical (B.C.M) Ltd.
• Inventors: Ben-David, Tamir
• Primary Examiner(s): KAHELIN, MICHAEL WILLIAM
• Application Number:
  US11/234,877
• Publication Number:
  US 20060100668A1
• Time in Patent Office: 1,965 Days
• Field of Search: 607/2
• US Class Current: 607/2
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362

Abstract

This invention provides a method for treating a condition of a subject, comprising identifying the subject as suffering from heart failure; treating the heart failure by applying a stimulating current to parasympathetic nervous tissue of the subject, and configuring the stimulating current to change a level of protein expression of at least one NO synthase of the subject selected from the group consisting of: NOS-1, NOS-2, and NOS-3; and thereafter, measuring the level of the protein expression of at least one NO synthase, and evaluating an effectiveness of the current application by assessing at least one change in the level of the protein expression of at least one NO synthase.

Claims

1. A method for treating a condition of a subject, comprising:

identifying the subject as suffering from heart failure;

treating the heart failure by applying a stimulating current to parasympathetic nervous tissue of the subject, and configuring the stimulating current to change a level of protein expression of at least one NO synthase of the subject selected from the group consisting of;

NOS-1, NOS-2, and NOS-3; and

thereafter, measuring the level of the protein expression of the at least one NO synthase, and evaluating an effectiveness of the current application by assessing at least one change in the level of the protein expression of the at least one NO synthase, the change selected from the group consisting of;

a reduction in the level of the protein expression of NOS-1, a reduction in the level of the protein expression of NOS-2, and an increase in the level of the protein expression of NOS-3.

2. The method according to claim 1, wherein configuring the stimulating current comprises configuring the stimulating current to reduce the level of the protein expression of NOS-1 and the level of the protein expression of NOS-2, and to increase the level of the protein expression of NOS-3.

3. The method according to claim 1, wherein applying the stimulating current comprises applying the stimulating current during a period having a duration of at least one week.

4. The method according to claim 1, wherein configuring the stimulating current comprises configuring the stimulating current to change the level of the protein expression of the at least one NO synthase of heart tissue of the subject.

5. The method according to claim 1, wherein the parasympathetic tissue includes a vagus nerve of the subject, and wherein applying the stimulating current comprises applying the stimulating current to the vagus nerve.

6. The method according to claim 1, wherein the parasympathetic tissue includes an epicardial fat pad of the subject, and wherein applying the stimulating current comprises applying the stimulating current to the epicardial fat pad.

7. The method according to claim 1, wherein the parasympathetic tissue is selected from the group consisting of:

parasympathetic tissue of a pulmonary vein, parasympathetic tissue of a carotid artery, parasympathetic tissue of a carotid sinus, parasympathetic tissue of a coronary sinus, parasympathetic tissue of a vena cava vein, parasympathetic tissue of a right ventricle, and parasympathetic tissue of a jugular vein, and wherein applying the stimulating current comprises applying the stimulating current to the selected parasympathetic tissue.

8. The method according to claim 1, wherein measuring the level of the protein expression of the at least one NO synthase comprises quantifying the level of the protein expression in densitometric units (du).

9. The method according to claim 8, wherein measuring the level of the protein expression comprises measuring the level of the protein expression of the at least one NO synthase in myocardium of the subject.

10. The method according to claim 5, wherein configuring the stimulating current comprises delivering the stimulating current in a series of bursts that commence in respective cardiac cycles after a delay after a feature of an electrocardiogram (ECG), each of which bursts includes up to 8 pulses having a pulse repetition interval of greater than 3 ms, and each of which pulses has a duration of between 0.2 and 4 ms, and an amplitude of between 2 and 10 mA.

11. The method according to claim 10, wherein configuring the stimulating current comprises commencing the bursts in the respective cardiac cycles after a delay from detection of an R-wave.

12. The method according to claim 10, wherein configuring the stimulating current comprises setting the amplitude to between 4 and 8 mA.

13. The method according to claim 10, wherein configuring the stimulating current comprises setting the pulse width to 1 ms.

14. The method according to claim 10, wherein configuring the stimulating current comprises setting the pulse repetition interval to 5 ms.

15. The method according to claim 10, wherein configuring the stimulating current comprises commencing the bursts in the respective cardiac cycles after a delay from detection of an R-wave, setting the amplitude to between 4 and 8 mA, setting the pulse width to 1 ms, and setting the pulse repetition interval to 5 ms.

16. The method according to claim 1, wherein assessing comprises assessing the reduction in the level of the protein expression of NOS-1, the reduction in the level of the protein expression of NOS-2, and the increase in the level of the protein expression of NOS-3.